Cullinan Oncology is a biopharmaceutical company. Zipalertinib (CLN-081/TAS6417) which Co. is co-developing with an affiliate of Taiho Pharmaceutical, Co. Ltd (Taiho), is an orally bioavailable small-molecule, irreversible epidermal growth factor receptor (EGFR) inhibitor that is designed to selectively target cells expressing EGFR exon 20 insertion (EGFRex20ins) mutations with relative sparing of cells expressing wild-type EGFR. In addition to zipalertinib, Co.'s portfolio includes four other clinical-stage product candidates and one product candidate that is pending the U.S. Food and Drug Administration clearance for its investigational new drug application. The CGEM average annual return since 2021 is shown above.
The Average Annual Return on the CGEM average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether CGEM average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CGEM average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|